

bossed in the upper left-hand corner of the foil backing. If the number 46460 appears on any of your samples, please return them to us as indicated below.

We also ask that you contact any patients to whom you may have given Diabinese samples recently. If by chance you received and gave to a patient a sample from this lot identifying the contents as 250 mg. Diabinese, when in fact the contents were 100 mg. tablets, the patient would obviously be taking less medication than you prescribed. Our professional Sales Representatives would have distributed samples from this lot to physicians no earlier than December 15, 1965, so it will be necessary for you to contact only those patients to whom you may have given these samples between December 15th and the date of this letter.

If you find any Diabinese samples from lot 46460, even if they bear the correct card identifying them as 100 mg. tablets, please promptly mail them to: Mr. John Mayreis, Chas. Pfizer & Co., Inc., 630 Flushing Avenue, Brooklyn, N.Y. 11206.

We wish to thank you for your cooperation in this matter, and to express our regrets for any inconvenience it may cause you or your patients. Please let us know if there is anything we can do to assist you.

Very truly yours,

JOHN L. WATTERS, M.D.,
Medical Director

PFIZER LABORATORIES,
DIVISION, CHAS. PFIZER & Co., INC.,
New York, N.Y., March 15, 1966.

IMPORTANT DRUG ALERT

DEAR DOCTOR: During the course of distribution to our Professional Sales Representatives of one lot of professional sample packages of $\frac{1}{4}$ mg. Renese tablets, we found that some of the white shipping cartons containing 18 sample packages (6 tablets per package) were incorrectly labeled as 2 mg. Renese tablets, lot 51425. The sample packages themselves are properly labeled as $\frac{1}{4}$ mg. Renese tablets.

Normally in supplying your needs for professional samples, our Professional Sales Representatives would not have supplied this shipping carton to you. Since we cannot rule this out as a possibility in every case, however, we are taking this opportunity of writing to you.

We therefore ask that you inspect all the Renese tablet professional samples that you have on hand. Please immediately destroy any white shipping cartons you may have in your possession which bear the following information on the flap:

Renese 2 Mg. (6 Tablets), Lot No. 51425, 18 Detail Samples

Whether these white shipping cartons contained 2 mg. tablets (yellow) or $\frac{1}{4}$ mg. tablets (white), the individual sample packages bear the correct identification. Neither the labeling of the sample packages nor the potency of the medication are at all in question.

Should you find as a result of this review of your samples that you require clarification or additional drug, please call upon your Pfizer Laboratories representative. Thank you for your cooperation in this matter.

Sincerely,

JOHN L. WATTERS, M.D.,
Medical Director

ROCHE LABORATORIES,
DIVISION OF HOFFMANN-LA ROCHE, INC.,
Nutley, N.J., March 9, 1966.

IMPORTANT: DRUG RECALL

DEAR DOCTOR: On February 28, we received a letter from FDA Commissioner James L. Goddard advising us of his intention to remove Madricidin from the market by regulatory means unless we chose immediately to withdraw the product.

Despite our belief that this should not be done, we have no practical alternative but to accede to the demand of the Food and Drug Administration to